ReviR Therapeutics Secures $30 Million Series A Funding for AIEnabled Drug Discovery Platform
ReviR Therapeutics, an AIenabled biotechnology company specializing in small molecule RNA modulators for neurogenetic diseases, has successfully completed a $30 million Series A financing round. This brings their total funding to $54 million, including previous seed financing. The funding will be utilized to enhance ReviRs AIdriven drug discovery platform, VoyageR, focusing on proprietary chemical matter development for novel targets and supporting clinical trials for Huntingtons disease, CharcotMarieTooth disease, amyotrophic lateral sclerosis, and other neurological disorders.
The funding round was led by Lapam Capital, with support from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the CharcotMarie Tooth Research Foundation (CMTRF). ReviR Therapeutics, founded in 2021, has assembled a global drug discovery team and developed a customized AI platform. Their approach involves developing noninvasive, orally administered genetic therapies using small molecules to regulate RNA splicing and influence protein expression to address previously undruggable targets.
The companys focus on targeting RNA upstream of protein synthesis aims to halt disease progression at the molecular level. ReviRs platform strategy seeks to develop potent, safe, and selective RNA splicing modulators for a wide range of diseases, particularly neurological disorders and rare genetic conditions. ReviR is also exploring partnerships in oncology, immunology, inflammation, and metabolic diseases while emphasizing accessibility and safety in genetic therapies.
Additionally, ReviRs collaboration with XtalPi leverages advanced AI and robotics drug discovery solutions to optimize RNA structural analysis, small molecule screening, and target engagement evaluation. This partnership is aimed at accelerating innovative RNAtargeted therapies into clinical research, expanding the potential of RNA targets, and delivering effective treatments globally.
